메뉴 건너뛰기




Volumn 37, Issue 2, 2014, Pages 148-153

Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer

Author keywords

Advanced non small cell lung cancer; Epidermal growth factor receptor (EGFR); Gefitinib; Stereotactic body radiation therapy (SBRT)

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

EID: 84900497923     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31826e071b     Document Type: Article
Times cited : (26)

References (33)
  • 2
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
    • (2002) N Engl J Med , vol.346 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 3
    • 0037214171 scopus 로고    scopus 로고
    • A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
    • Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39:55-61.
    • (2003) Lung Cancer , vol.39 , pp. 55-61
    • Massarelli, E.1    Andre, F.2    Liu, D.D.3
  • 5
    • 0347364778 scopus 로고    scopus 로고
    • Targeting the epidermal growth factor receptor in non-small cell lung cancer
    • Herbst R, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003;9:5813-5824.
    • (2003) Clin Cancer Res , vol.9 , pp. 5813-5824
    • Herbst, R.1    Bunn Jr., P.A.2
  • 6
    • 0034644539 scopus 로고    scopus 로고
    • Cell signaling by receptor tyrosine kinases
    • Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
    • (2000) Cell , vol.103 , pp. 211-225
    • Schlessinger, J.1
  • 7
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
    • (2008) N Engl J Med , vol.358 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 8
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 9
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3
  • 10
    • 33646867322 scopus 로고    scopus 로고
    • Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
    • Cufer T, Vrdoljak E, Gaafar R, et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs. 2006;17:401-409.
    • (2006) Anticancer Drugs , vol.17 , pp. 401-409
    • Cufer, T.1    Vrdoljak, E.2    Gaafar, R.3
  • 11
    • 74949133978 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251-6266.
    • (2009) J Clin Oncol , vol.27 , pp. 6251-6266
    • Azzoli, C.G.1    Baker Jr., S.2    Temin, S.3
  • 12
    • 63749100778 scopus 로고    scopus 로고
    • Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases
    • Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579-1584.
    • (2009) J Clin Oncol , vol.27 , pp. 1579-1584
    • Rusthoven, K.E.1    Kavanagh, B.D.2    Burri, S.H.3
  • 13
    • 4844229902 scopus 로고    scopus 로고
    • Stereotactic hypofractionated high-dose irradiation for stage i non small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study
    • Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623-1631.
    • (2004) Cancer , vol.101 , pp. 1623-1631
    • Onishi, H.1    Araki, T.2    Shirato, H.3
  • 14
    • 65549125983 scopus 로고    scopus 로고
    • Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patternsof-failure analysis
    • Rusthoven KE, Hammerman SF, Kavanagh BD, et al. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patternsof-failure analysis. Acta Oncol. 2009;48:578-583.
    • (2009) Acta Oncol , vol.48 , pp. 578-583
    • Rusthoven, K.E.1    Hammerman, S.F.2    Kavanagh, B.D.3
  • 15
    • 51449118059 scopus 로고    scopus 로고
    • Stereotactic body radiotherapy for oligometastatic lung tumors
    • Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72:398-403.
    • (2008) Int J Radiat Oncol Biol Phys , vol.72 , pp. 398-403
    • Norihisa, Y.1    Nagata, Y.2    Takayama, K.3
  • 16
    • 33748859087 scopus 로고    scopus 로고
    • Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: Marker placement and early results
    • Nuyttens JJ, Prevost JB, Praag J, et al. Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: marker placement and early results. Acta Oncol. 2006;45:961-965.
    • (2006) Acta Oncol , vol.45 , pp. 961-965
    • Nuyttens, J.J.1    Prevost, J.B.2    Praag, J.3
  • 17
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 18
    • 0036184207 scopus 로고    scopus 로고
    • What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592
    • Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55:285-295.
    • (2002) J Clin Epidemiol , vol.55 , pp. 285-295
    • Cella, D.1    Eton, D.T.2    Fairclough, D.L.3
  • 19
    • 1242293093 scopus 로고    scopus 로고
    • Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors
    • Ochs JS. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys. 2004;58:941-949.
    • (2004) Int J Radiat Oncol Biol Phys , vol.58 , pp. 941-949
    • Ochs, J.S.1
  • 20
    • 69949110700 scopus 로고    scopus 로고
    • Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy
    • Park HJ, Kim KJ, Park SH, et al. Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy. AJR Am J Roentgenol. 2009;193:209-213.
    • (2009) AJR Am J Roentgenol , vol.193 , pp. 209-213
    • Park, H.J.1    Kim, K.J.2    Park, S.H.3
  • 21
    • 33646883312 scopus 로고    scopus 로고
    • Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors
    • Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol. 2006;23:161-170.
    • (2006) Med Oncol , vol.23 , pp. 161-170
    • Tsuboi, M.1    Le Chevalier, T.2
  • 22
    • 79960055286 scopus 로고    scopus 로고
    • Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience
    • Chang CC, Chi KH, Kao SJ, et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011;73: 189-194.
    • (2011) Lung Cancer , vol.73 , pp. 189-194
    • Chang, C.C.1    Chi, K.H.2    Kao, S.J.3
  • 23
    • 79953777978 scopus 로고    scopus 로고
    • Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor
    • Okamoto I, Takahashi T, Okamoto H, et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer. 2011;72:199-204.
    • (2011) Lung Cancer , vol.72 , pp. 199-204
    • Okamoto, I.1    Takahashi, T.2    Okamoto, H.3
  • 24
    • 76149123903 scopus 로고    scopus 로고
    • A phase i study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small-cell lung cancer
    • Center B, Petty WJ, Ayala D, et al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small-cell lung cancer. J Thorac Oncol. 2010;5:69-74.
    • (2010) J Thorac Oncol , vol.5 , pp. 69-74
    • Center, B.1    Petty, W.J.2    Ayala, D.3
  • 25
    • 0025009172 scopus 로고
    • A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
    • Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945.
    • (1990) N Engl J Med , vol.323 , pp. 940-945
    • Dillman, R.O.1    Seagren, S.L.2    Propert, K.J.3
  • 26
    • 0021260822 scopus 로고
    • Primary tumor control after radiotherapy for carcinoma of the bronchus
    • Saunders MI, Bennett MH, Dische S, et al. Primary tumor control after radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys. 1984;10:499-501.
    • (1984) Int J Radiat Oncol Biol Phys , vol.10 , pp. 499-501
    • Saunders, M.I.1    Bennett, M.H.2    Dische, S.3
  • 27
    • 74549188119 scopus 로고    scopus 로고
    • Systemic review of the patterns of failure following stereotactic body radiation therapy in earlystage non-small-cell lung cancer: Clinical implications
    • Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in earlystage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1-11.
    • (2010) Radiother Oncol , vol.94 , pp. 1-11
    • Chi, A.1    Liao, Z.2    Nguyen, N.P.3
  • 28
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)
    • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2009;27:2237-2246.
    • (2009) J Clin Oncol , vol.27 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 29
    • 34248385777 scopus 로고    scopus 로고
    • Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
    • Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847-855.
    • (2006) J Thorac Oncol , vol.1 , pp. 847-855
    • Chang, A.1    Parikh, P.2    Thongprasert, S.3
  • 30
    • 52049125250 scopus 로고    scopus 로고
    • Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    • Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26: 4244-4252.
    • (2008) J Clin Oncol , vol.26 , pp. 4244-4252
    • Maruyama, R.1    Nishiwaki, Y.2    Tamura, T.3
  • 31
    • 76749154617 scopus 로고    scopus 로고
    • Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
    • Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010;16:1307-1314.
    • (2010) Clin Cancer Res , vol.16 , pp. 1307-1314
    • Lee, D.H.1    Park, K.2    Kim, J.H.3
  • 32
    • 79958120436 scopus 로고    scopus 로고
    • A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy
    • Chen YM, Fan WC, Tsai CM, et al. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J Thorac Oncol. 2011;6:1110-1116.
    • (2011) J Thorac Oncol , vol.6 , pp. 1110-1116
    • Chen, Y.M.1    Fan, W.C.2    Tsai, C.M.3
  • 33
    • 80255123376 scopus 로고    scopus 로고
    • Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer
    • Widder J, Postmus D, Ubbels JF, et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:e291-e297.
    • (2011) Int J Radiat Oncol Biol Phys , vol.81
    • Widder, J.1    Postmus, D.2    Ubbels, J.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.